THE STUDY OF THE ABNORMAL IMMUNOGLOBULIN TYPES RELATED TO DISEASE AND FREQUENCY OF EXAMINATION IN PATIENTS AT SRINAGARIND HOSPITAL, FACULTY OF MEDICINE, KHON KAEN UNIVERSITY, THAILAND

Authors

  • Thipaporn Jaroonsirimaneekul Diagnostic Laboratory, Sringarind Hospital, Faculty of Medicine, Khon Kaen University
  • Prinya Prasongdee Diagnostic Laboratory, Sringarind Hospital, Faculty of Medicine, Khon Kaen University
  • Puangpaka Sadee Diagnostic Laboratory, Sringarind Hospital, Faculty of Medicine, Khon Kaen University
  • Chanpen Sripan Diagnostic Laboratory, Sringarind Hospital, Faculty of Medicine, Khon Kaen University
  • Kutcharin Phunikhom Department of Pharmacology, Faculty of Medicine, Khon Kaen University
  • Nunthaphan Kanoksirirujisaya Department of Industrial Engineering, Faculty of Engineering, Thonburi University

Keywords:

Multiple Myeloma (MM.), Immunofixation Test (IFE.)

Abstract

The study of the abnormal immunoglobulin types related to disease and frequency of examination in patients at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand aimed to study Multiple Myeloma (MM.) of patients with hematological cancer caused by abnormalities in plasma cells which is a group of white blood cells. In Multiple Myeloma patients, plasma cells grow abnormally. Resulting in abnormalities in the body. Most of them are created and detected abnormal immunoglobulins, which can be distinguished and confirmed with an Immunofixation Test (IFE.), while at the same time IFE is not a test. For screening, it's just a test to confirm the type of disease. In smaller hospitals, tests of this nature may not be available to support the service. However, the fee for IFE. examination in the Comptroller General's Department system is charged up to 3,000 baht per time, so the results of the IFE. study are suitable for examination to confirm the type of disease and should be tested no more than 2 times a year due to the form of immunoglobulin often does not change. For patients with Nephrotic Syndrome, an IFE. test once a year is considered appropriate since MM. patients are often predisposed to impaired renal function. The study also found that in patients with no non specific diagnosis, IFE. was tested, possibly because the doctor wanted to determine or exclude the diagnosis to rule out the risk of MM. At the same time, SPEP was used to monitor patients. It can help a lot. And the price is very different from IFE examination, where SPEP costs 300 baht per time, and especially in the MM. group, it was found that the SPEP results can be evaluated by up to 95.8% of patients. Keywords: Multiple Myeloma (MM.) , Immunofixation Test (IFE.)

References

Barnidge, D.R., Dasari, S., Botz, C.M. (2014). Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. Journal of Proteome Research. 13(3), 1419-1427.

Barnidge, D.R., Dasari, S., Ramirez-Alvarado, M. (2014). Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry. Journal of Proteome Research. 7;13(11), 5198-205.

Christopher H., Shikhar G.V., Gurmukh S. (2016). Audit of Use and Overuse of Serum Protein Immunofixation Electrophoresis and Serum Free Light Chain Assay in Tertiary Health Care: A Case for Algorithmic Testing to Optimize Laboratory Utilization. American Journal of Clinical Pathology. 145, 531-537.

Dispenzieri, A., Katzmann, J.A., Kyle, R.A. (2010). Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. The Lancet. 375(9727), 1721-1728.

U.S. Food & Drug Administration. (2021 March, 27). FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma. https://www.fda.gov/news-events/pressannouncements/fdaapproves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma

Fouquet, G., Schraen, S., Faucompre, J.L. (2014). Hevylite® to monitor response to therapy in multiple myeloma. American Society of Hematology. 124(21), 20-21.

Gertz, M.A., Kyle, R.A. (1995). Hyperviscosity syndrome. Journal of Intensive Care Medicine. 10(3). 128-141.

Katzmann, J.A., Willrich, M.A.V., Kohlhagen, M.C. (2015). Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clinical Chemistry. 61(2), 360-367.

Kyle, R.A., Child, J.A., Anderson, K. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology. 121(5), 749-757.

Kyle, R.A., Katzmann, J.A., Lust, J.A., Dispenzieri, A. (2002). Clinical indications and applications of electrophoresis and immunofixation. ASM Press: Washington DC.

Milani, P., Murray, D.L., Barnidge, D.R. (2017). The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. American Journal of Hematology. 92(8), 772-779.

Mills, J.R., Barnidge, D.R., Murray, D.L. (2015). Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods. 81, 56-65.

O’Connell, T.X., Horita, T.J., Kasravi, B. (2015). Understanding and interpreting serum protein electrophoresis. American Family Physician. 71(1), 105-112.

Tomer, M. (2021). A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma. https://www.researchgate.net/scientific-contributions/Tomer-M-Mark-38176968.

Downloads

Published

2022-12-30

How to Cite

Jaroonsirimaneekul, T., Prasongdee, P., Sadee, P., Sripan, C., Phunikhom, K., & Kanoksirirujisaya, N. (2022). THE STUDY OF THE ABNORMAL IMMUNOGLOBULIN TYPES RELATED TO DISEASE AND FREQUENCY OF EXAMINATION IN PATIENTS AT SRINAGARIND HOSPITAL, FACULTY OF MEDICINE, KHON KAEN UNIVERSITY, THAILAND. Journal of Science and Technology Thonburi University, 6(2), 8–16. retrieved from https://ph03.tci-thaijo.org/index.php/trusci/article/view/519

Issue

Section

Research Articles